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Abstract: Hypogonadotropic hypogonadism is defined as a medical condition with low or 
undetectable gonadotropin secretion, associated with a complete arrest of follicular growth and 
very low estradiol. The main cause can be traced back to an irregular or absent hypothalamic 
GnRH secretion, whereas only a minority suffers from a pituitary disorder. The choice of treat-
ment to reverse this situation is a pulsatile GnRH application or a direct ovarian stimulation 
using gonadotropin injections. The goal is to achieve a proper ovarian function in these cases 
for a short time to allow ovulation and chance of pregnancy. Since the pulsatile GnRH treatment 
lost its former importance, several gonadotropins are in use to stimulate follicular growth, such 
as urine-derived human menopausal gonadotropin, highly purified follicle stimulating hormone 
(FSH) or recombinant FSH, all with different success. The introduction of recombinant lutein-
izing hormone (LH) and FSH provided an opportunity to investigate the distinct influences of 
LH and FSH alone and in combination on follicular growth in monofollicular ovulation induction 
cycles, and additionally on oocyte maturation, fertilization competence of the oocyte and embryo 
quality in downregulated IVF patients. Whereas FSH was known to be indispensable for normal 
follicular growth, the role of LH remained questionable. Downregulated IVF patients with this 
short-term gonadotropin depletion displayed no advance in stimulation success with the use of 
recombinant LH. Patients with hypogonadotropic hypogonadism undergoing monofollicular 
stimulation for ovulation induction showed clearly a specific role and need for both hormones 
in normal follicular growth. Therefore, a combined stimulation with FSH and LH seems to be 
the best treatment choice. In the first half of the stimulation cycle the FSH dosage should exceed 
that of LH by 2:1, with an inverse ratio for the second half.
Keywords: hypogonadotropic hypogonadism, ovarian stimulation, ovulation induction, recom-
binant luteinizing hormone
Introduction
Hypogonadotropic hypogonadism (HH) is a rare disease, characterized by low or 
undetectable levels of luteinizing hormone (LH) and follicle stimulating hormone 
(FSH) and a chronic estradiol deficiency, due to a complete arrest of follicular growth 
with subsequent amenorrhea. The low or undetectable gonadotropins portray the 
common endpoint of different diseases and circumstances. Despite a few cases of 
pituitary origin such as adenomas or inflammation (hypophysitis), the majority of HH 
patients suffer from a disturbed hypothalamic gonadotropin-releasing hormone (GnRH) 
secretion.1,2 The irregular GnRH secretion can be traced back to a morphological Biologics: Targets & Therapy 2009:3 338
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correlate such as Kallmann’s syndrome, adrenal hypoplasia 
congenita (in men), GnRH gene mutation or Leptin gene 
mutation in just 10% of all cases.3,4 The remaining 90% 
can be subsumed as a functional disturbance of pulsatile 
GnRH secretion, caused by eating disorders, emotional 
stress or excessive exercise (long distance runners). In the 
latter, diagnosis can only be made by exclusion of other 
abnormalities.5
Regardless of the origin and underlying cause, HH 
also means profound infertility. Therefore, many attempts 
had been made to override the arrest of follicular growth 
and achieve a regular ovulatory function of these ovaries. 
From pulsatile GnRH application as the most physiological 
treatment to daily injections of different gonadotropins 
with different stimulation protocols have all been done to 
achieve normal follicular growth and chance of pregnancy. 
HH women with their long lasting gonadotropin depletion 
represent a very distinct group of patients in reproductive 
medicine. In this review, we will describe and discuss the 
influence of LH and FSH on normal follicular growth and 
the results of different stimulation protocols in the treat-
ment of HH women to achieve monofollicular growth for 
ovulation induction, with special attention on the effect of 
LH. Additionally, several studies dealing with IVF patients 
as a model for HH women will be discussed to prove the 
influence of LH on oocyte quality, fertilization competence 
and embryo quality.
GnRH secretory patterns  
and follicular growth
GnRH, a 10 amino acid peptide, will be produced (mainly) 
by hypothalamic neurons to stimulate the gonadotropic cells 
in the pituitary.
The hypothalamic–pituitary–gonadal axis is driven by 
a neuronal pacemaker, located in the mediobasal hypothal-
amus, on the bottom of the third ventricle. Approximately 
15,000 neurons release GnRH in a pulsatile fashion from the 
eminentia mediana into the portal vein system.6
GnRH stimulates the production of LH and FSH in 
the pituitary and the pulsatile release of LH, and in part of 
FSH,7,8 whereas GnRH pulsatility influences FSH bioactivity 
more than its secretion.7 Several neurotransmitters such as 
GABA,9 endogenous opioids,10 neuropeptide Y,11 galanin12 
or norepinephrine13 are involved in the regulation of pulsatile 
GnRH secretion.
Even slight changes in GnRH pulse frequency disturb 
fundamentally LH and FSH secretion and also their 
bioactivity.2,14 Normal follicular growth will slow down 
until a complete arrest of follicular growth. Menstrual 
irregularities, anovulation or oligomenorrhea are the external 
signs of this malfunction. In the more severe cases, this will 
lead to a complete ovarian failure and subsequent lost of 
menstrual bleeding, a central or hypothalamic amenorrhea.
Despite the irregular GnRH secretory patterns, the 
pituitary LH- and FSH-producing cells remain fullly sensi-
tive to (external) normal GnRH secretion, at least for a while. 
This is one concept in the treatment of HH.15–17
Ovarian physiology related  
to LH and FSH secretion
Maturation of the follicles
Follicular development from the primordial to the preovulatory 
stage occurs continuously in a random fashion and takes 
several months from the very early primordial follicles 
(primary or initial recruitment) until one follicle reaches the 
preovulatory stage.18 In this way, most of the developing 
follicles became atretic by apoptosis.
The early stages of follicular growth are independent from 
FSH. From the primary follicle onward, FSH receptors can be 
found,19 assuming a FSH dependency from this stage. Ovaries 
from HH women (Kallmann’s syndrome) showed only a few 
follicles that had passed the primordial stage.20 Otherwise, as 
recently shown, follicular growth can still progress further 
in the absence of FSH until the antral stage.21
Follicular phase characteristics
At the end of the luteal phase, with demise of the corpus 
luteum, estradiol, progesterone and inhibin A decline. 
The falling progesterone level compromises the hypotha-
lamic endogenous opioid tone, which will enable the GnRH-
producing neurons to enhance their firing rate.7,22,23
The subsequent increase in GnRH pulse frequency 
enhances pituitary FSH and LH production,7,24 and in face of 
a diminished inhibin A,25 the FSH level rises sharply to pass 
the threshold level for the secondary (or cyclic) recruitment 
of the next follicle cohort.26 Due to the FSH increase, this 
follicle cohort escapes apoptosis and continues to grow.
At this time LH stimulates follicular theca cells to produce 
androgens (androstendione). These androgens are required 
for estrogen synthesis by FSH-driven granulosa cells:27 the 
concept of the classic two cell–two gonadotropin model.
Additionally, FSH has been found to be necessary for 
normal androgen production,21 and an androgen-promoted 
stimulation of granulosa cell aromatase activity in antral 
follicles has been described,28 an LH arbitrated process.Biologics: Targets & Therapy 2009:3 339
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Throughout the follicular phase and with rising estradiol 
and inhibin levels the amount of circulating FSH declines 
continuously, whereas LH levels begin to climb29 and end 
in the preovulatory LH surge, with resumption of meiosis as 
the most significant LH function.30
Around the midfollicular stage, the increasing GnRH pulse 
frequency favors LH secretion. This higher GnRH pulse fre-
quency also increases the bioactivity of secreted LH isoformes 
and decreases their half-life, resulting in an attenuated LH 
pulse amplitude in face of a higher LH pulse frequency.14,31 The 
resulting higher LH action drives the androgen output by the 
theca cells.32 These enhanced intrafollicular androgen levels 
acquire an amplified granulosa cell activity to avoid a massive 
intrafollicular accumulation of androgens, because this high 
androgenetic milieu promotes follicular atresia.33 Nevertheless, 
the intrafollicular androgens (at normal level) can improve the 
follicular development and oocyte quality.34
With the declining FSH, a much higher sensitivity to the 
remaining FSH will be needed to sustain sufficient granulosa 
cell activity. Additionally, with the rising estradiol level 
along the follicular phase, FSH changes its isoform to one 
of higher bioactivity,35 to compensate partly for the declining 
amount of FSH secreted.
The dominant follicle
Among the cohort of about 10 recruited follicles, normally 
only one follicle will arrive at the preovulatory stage with 
the ability to ovulate. This follicle grows faster and produces 
more estradiol, which is needed to inhibit the androge-
netic driven apoptosis in the follicle,36 and inhibin than the 
others.18 Within this cohort only the dominant follicle reaches 
the capability to continue to develop in face of diminish-
ing FSH.37
The leading position of the dominant follicle results 
from a higher sensitivity to FSH, due to a higher amount 
of FSH (and LH?) receptors or may be greater influenced 
by local (intrafollicular) growth factors, as these could act 
independently from FSH or just augment the FSH respon-
siveness.18
Since FSH has been recognized as a conditio sine qua 
non for normal oocyte development,38 in the past LH was 
conceded only a minor role in follicle maturation.
According to the two cells–2 gonadotropins model men-
tioned above, the LH action was restricted to the stimulation 
of follicular theca cells to produce androgens as a precursor 
of estradiol. These androgens in turn traverse the follic-
ular basement membrane for aromatization by FSH-driven 
granulosa cells.27
Each cell type has one specific receptor type and interacts 
only with LH or FSH.
With the midfollicular stage, when a follicle reaches 10 to 
14 mm in diameter, granulosa cells increasingly express 
LH receptors39,40 until the late follicular phase,41 indicating 
a role for LH in final follicular development and oocyte 
maturation.39 The LH receptor gene expression is mediated 
by FSH42,43 and may be facilitated by estradiol.44
With the inhibin-induced decreasing FSH levels at this 
time,45 LH seems to sensitize the dominant follicle for the 
remaining low FSH and allows further growth.39 But in 
fact LH just takes over some of the action of the vanish-
ing FSH.46
Beside this, the rising LH levels lead also to an arrest of 
midsized follicles to secure monofollicular development and 
avoid multiple ovulations.47,48
Intraovarian modulators such as insulin growth factor- 
(IGF-1), epidermal growth factor and tumor necrosis factor 
are also involved in the regulation of follicular growth by 
influencing theca and granulosa cell activity.26
In the past, the sensitizing of the dominant follicle to 
FSH was attributed to a higher amount of FSH receptors in 
the dominant follicle to allow more binding of the remaining 
few FSH molecules than the other less developed follicles. 
But with the existence of LH receptors on granulosa cells, 
this theory needs to be revised.
Obviously, from the midfollicular stage, LH partly takes 
over FSH action on granulosa cells. This could explain why 
the maturing dominant follicle becomes more independent 
from FSH.49 Interestingly, LH stimulates steroid genesis in 
mature granulosa cells, but inhibits further cell proliferation. 
Both the FSH-driven cell proliferation and the LH-induced 
inhibition are mediated by IGF-1.50
These results demonstrate an inverse relationship between 
proliferation and steroid synthesis of granulosa cells as they 
differentiate.
The rising LH level enhances the androgen biosynthesis 
by theca cells, and in the face of a declining aromatase activity 
in the smaller, LH-receptor-free follicles, the high intrafol-
licular androgenetic milieu in these follicles will promote a 
follicular atresia.46 Thus, the LH receptor gene expression 
on granulosa cells is necessary to avoid follicular apoptosis 
and therefore represents one basic factor in the selection of 
the dominant follicle.
The expression of LH receptors on maturing granulosa 
cells in concert with climbing LH levels depict the key factors 
for the selection of the dominant follicle, to keep this follicle 
alive in face of diminished FSH33 and to avoid additional Biologics: Targets & Therapy 2009:3 340
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follicular growth with subsequent multiple ovulations by an 
enhanced apoptosis rate in midsized follicles.51
Once the follicular size has reached 14 mm in diameter, 
LH stimulation without FSH becomes able to continue further 
follicular growth.42,52
After the FSH-triggered secondary recruitment of the 
follicle cohort, a critical amount of LH and FSH will be neces-
sary to maintain follicular growth and oocyte maturation.53 
Additionally, the ability of the preovulatory follicles to trans-
fer their gonadotropic dependence from FSH to LH seems 
to be absolutely crucial for follicle selection.54
Both hormones exert very different effects on granulosa 
cell gene expression55 or the extent of granulosa cell steroido-
genesis prior to and after ovulation.56
The picture completely differs in men, where LH acts 
only on Leydig cells and FSH only on Sertoli cells without 
any cross action.57
LH pharmacology
LH shares an identical alpha-subunit with other hormones as 
part of a family of heterodimeric proteohormones (thyroid-
stimulating hormone, human chorionic gonadotrophin 
[HCG], FSH). The hormone unique beta-subunit confers the 
biological action and the ability to bind to a specific receptor. 
Both subunits are associated with noncovalent bonds.58,59
Until the end of the previous century, human menopausal 
gonadotropin (HMG) was the only commercially available 
source of LH activity. This preparation contains LH and FSH, 
derived from the urine of postmenopausal women. Due to an 
unstable proportion of LH and a reduced LH bioactivity in 
comparison to normal cycling women,31,60 HCG was added as 
a LH substitute to allocate a 1:1 ratio of LH and FSH action,61 
which means that HMG preparations contain different 
amounts of HCG. The LH and HCG beta-subunits are identi-
cal in 82% of their amino acid sequence,62 which will allow 
HCG to act on LH receptors. The HCG beta-subunit genes 
appear to have evolved from an ancestral LH beta-subunit 
gene by multiple gene duplication and rearrangements.62
With the introduction of recombinant LH (lutropin alpha) 
to the market, a preparation with a defined LH activity 
became available for clinical use.
Luveris® (lutropin-α; Serono SA), under extensive test-
ing since 1993, has been first registered in the European 
Union in 2001.
The drug is characterized by a consistent isoform pro-
file with a high reproducible reliability.63 The fundamental 
advantage in the recombinant production of a gonadotropin 
is the highly and unreached purification, without any danger 
of contaminating the probe. In comparison to urine-derived 
LH with 60 to 250 IU LH/mg protein, the recombinant LH 
preparation contains 20,000 to 30,000 IU LH/mg protein.64
Along with the recombination of the isolated α- and 
β-subunits of the hormones, the whole process generates a 
highly sophisticated product with literally identical properties 
compared with the native hormone.
Recombinant LH was first studied in nonhuman 
primates.64 The pharmacokinetic trial, designed to compare 
and reveal possibly differences between pituitary, urine and 
recombinant LH and to ascertain the pharmacological prop-
erties, showed similar results for mean concentration time 
curves, mean clearance rates and half-life.
Gonadotropic treatment  
in HH women
HH describes a condition of very low or undetectable gonado-
tropins and subsequently arrested follicular growth with low 
estradiol levels, no ovulation and no menstrual bleeding. The 
accompanying infertility is the reason for the application 
of GnRH or gonadotropins to induce follicular growth and 
restore a normal chance to the patient to get pregnant. The 
majority of HH patient are scheduled for ovulation induction 
after monofollicular growth.
Pulsatile GnrH stimulation
Due to the most common cause of HH, the pulsatile GnRH 
treatment provides a suitable and effective strategy to 
restore a normal ovarian function.65 This therapy induces 
monofollicular development with physiological estradiol 
levels and subsequent luteal phase characteristics compa-
rable to a complete normal ovarian function. The pulsatile 
GnRH treatment showed results slightly superior to HMG 
stimulation for cumulative pregnancy rate.15 Unfortunately, 
many patients displayed psychological problems and were 
irritated by the carrying of an electronic pump on their body 
for several days or weeks.
Gonadotropins (HMG, FSH, LH)
Daily injections of gonadotropins have been established 
as a more feasible and tolerated alternative for ovulation 
induction, with comparable results.66 This therapy can be 
administered by intramuscular or subcutaneous injections 
of FSH alone or in combination with LH as urinary-derived 
HMG or more recently as a combination of recombinant FSH 
and LH. In contrast to the pulsatory GnRH therapy, one of the 
inherent dangers of this mainly non-physiological stimulation 
is an ovarian hyper-response with multiple follicular growth, Biologics: Targets & Therapy 2009:3 341
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followed by an ovarian hyperstimulation syndrome67 and a 
higher risk of multiple pregnancies.15 In the normal menstrual 
cycle, FSH declines and LH rises during the follicular phase. 
FSH dominates the first half of the follicular phase and LH 
the second half, with the appearance of LH receptors on 
granulosa cells.33 The normal follicular phase starts with high 
FSH and low LH levels. Alongside the follicular growth FSH 
decreases and LH climbs continuously. HMG, with a fixed 
LH-FSH ratio, represents an non-physiological stimulation, 
because of the inability to adjust different LH-FSH ratios 
during the stimulation.
With the introduction of highly purified FSH and, later, 
recombinant FSH, gonadotropic stimulation became FSH 
dominated over the whole period, which is also completely 
different from the normal cycle.
Very early with the FSH-only stimulation strategy, the 
necessity of LH in HH women to achieve a normal follicular 
growth and oocyte maturation was questioned.53,68–73 These 
first studies demonstrated clearly that stimulation of ovulation 
induction with FSH alone in LH-depleted women leads to 
a much higher consumption of the gonadotropin combined 
with reduced follicular growth, dramatically lower estradiol 
levels and overall ovulation rates. These non-IVF studies 
left the unsolved question of whether or not the fertilization 
competence of the oocyte will be compromised. An IVF 
treatment in a HH woman, using a higher FSH dosage than 
normally given in ovulation induction cycles, showed clearly 
that an LH-free stimulation induces normal follicular growth 
with accompanying low estradiol level and without normal 
oocyte maturation and fertilization competence.74 The poor 
oocyte quality results directly from the insufficient LH secre-
tion and is not caused by a low estradiol level.74 The oocyte 
requires both gonadotropins to achieve full maturation,75 but 
to what extent is not known.76
The second question on this topic is the influence of 
low estradiol level on the pregnancy rate.36 Animal studies 
had shown a clear dependency of the maturing process of 
the oocyte on normal estradiol levels.77,78 In humans, estra-
diol does not seem to be mandatory for the fertilization 
competence of the oocyte,74,79,80 but it is highly essential for 
pregnancy rate.81 Therefore, estradiol plays a key role in 
the normal development of the endometrium to achieve full 
receptivity to the embryo.
Gonadotropin stimulation in ivF patients 
as a LH depleted model
While FSH secretion could recognized as mandatory for 
normal follicular growth,38,53 some concerns were raised 
about the possibly of the deleterious influence of LH on 
oocyte fertilization rate and pregnancy outcome.82,83 High LH 
levels are known to be associated with a premature resump-
tion of meiosis in exposed oocytes84 and an inhibition of the 
granulosa cell proliferation.50 Additionally, with reports of 
higher pregnancy rates in downregulated IVF patients using 
FSH compared with HMG,85 the gain from LH became ques-
tionable. These observations have led to a concept of a LH 
“ceiling” level, beyond which normal follicular growth and 
oocyte quality will be compromised by LH.86
Through the very low incidence of HH, many studies 
on the influence of LH on follicular growth and oocyte 
quality embraced downregulated patients undergoing an IVF 
procedure. The downregulation with GnRH analogs results 
in very low gonadotropin levels. Despite some very distinct 
differences between the controlled ovarian hyperstimulation 
in IVF and the monofollicular stimulation in HH women, 
only the IVF procedure provides the opportunity to verify 
the influence of the different gonadotropin preparations on 
stimulation success like oocyte maturation, fertilization 
competence and pregnancy rate.
Multiple studies have been done to prove the superiority 
of a distinct gonadotropin preparation, with very conflicting 
results.85,87–92 These differences can be traced back, at least 
partly, to the incomplete downregulation through the GnRH 
agonists or antagonists, where secretion of LH continues to 
be detectable93,94 in varing amounts.95 No doubt has been 
raised about the necessity of a distinct amount of LH to 
ensure the resumption of meiosis,96 the most crucial process 
to achieve full chromosomal integrity and oocyte diploidy.97 
The discussion has focused on the impact of LH on oocyte 
maturation during the follicular phase. Even in massively 
downregulated women with LH levels near 1 U/L, no impact 
of these low LH levels on oocyte quality has been seen98 
and stimulation with pure FSH did not fail to induce 
normal follicular growth.99 With the introduction of highly 
purified and, later, recombinant FSH for stimulation in 
downregulated (LH depleted) patients, the need for LH 
became uncertain.99 Westergaard et al100 demonstrated that 
midfollicular LH levels below 0.5 U/L do not compromise 
follicular growth, oocyte fertilization competence or preg-
nancy rate in downregulated IVF patients. However, this very 
low LH action (0.5 U/L) during follicular development 
and oocyte maturation was related to an increased early 
pregnancy loss,100 with an impact on embryonic ploidy.92 
Can this higher risk of abortion be traced back to an impact 
of the minimal LH secretion on oocyte/embryo quality? Or 
a possible lower estradiol increase along the stimulation in Biologics: Targets & Therapy 2009:3 342
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the low LH group with impact on the endometrium, since 
in both groups estradiol levels were ample and much higher 
than in a normal cycle.
A further meta-analysis reported lower ongoing 
pregnancy rates in women with follicular phase LH levels 
higher than 1.5 U/L and no impact of low LH levels.101 All 
these studies were done on downregulated patients undergo-
ing an IVF procedure in order to prove the amount of LH 
necessary for the achievement of full fertilization competence 
of the oocyte. The use of the downregulated IVF patient as a 
model for HH women contains several limitations because 
the short-term suppression of LH and FSH in IVF cycles 
differs from the long lasting and more profound depletion 
of the gonadotropins in HH women.
A. Downregulated IVF patients display higher LH levels than 
HH women, depending on what GnRH analog was used.
B.  Because IVF patients are mainly normally cycling 
women, the LH depletion period is much shorter than in 
HH women.
C.  The intraovarian androgenetic milieu, necessary for 
normal oocyte maturation,34 differs completely.
Gonadotropin stimulation for ovulation 
induction in HH women
With the introduction of highly purified FSH and recombinant 
FSH, two preparations became available for FSH-only 
stimulation, even in HH women. Due to the rare incidence 
of HH, the first studies embraced just a few participants. 
In spite of these limitations, these first results showed clearly 
the necessity of a distinct amount of LH to achieve full 
oocyte maturation and ovulation competence.53,68–71,74
With respect to the studies discussed above on the 
influence of different gonadotropin preparations on oocyte 
quality in downregulated women undergoing an IVF proce-
dure, a threshold level for LH was proposed, necessary for 
normal follicular development and oocyte maturation.76,102 
Therefore, with a threshold and “ceiling” level of LH, Shoham 
postulated the concept of a therapeutic window for LH.102
impact of FSH-only stimulation on cycle quality 
and follicular maturation
Stimulation studies with highly purified or recombinant FSH 
showed a clear correlation between remaining LH levels 
and stimulation outcome in HH women.1,53,70,103 Below a 
LH level of 1 U/L, FSH alone was not capable of stimulat-
ing follicular growth.104 An earlier study by Schoot et al70 
clearly demonstrated, however, reduced follicular growth 
in 4 out of 7 women, all with LH levels below 0.5 U/L. 
Shoham et al73 reported on 2 HH women treated with 
recombinant FSH that both showed follicular growth 
with only a small increase in estradiol levels. This agrees 
with another study by Couzinet et al53 with an ovulation rate 
of 60%. In that study, women were treated with highly puri-
fied FSH, containing 0.09% LH bioactivity. In addition to the 
remaining circulating LH, the low LH activity was sufficient 
to sustain complete follicle maturation, since less than 1% 
of follicular LH receptors are needed to be stimulated by LH 
to maintain a proper follicular growth,105 in the presence of 
sufficient FSH.53
All these studies showed clearly that a FSH-only stimu-
lation posseses limited value because of an insufficient 
follicular growth53,70,104,106 and oocyte maturation74 with 
an increased number of midsized follicles48 and very low 
estradiol levels,69,70,73,104 and a subsequent low endometrial 
score.1,71 A clear correlation can be found apparently between 
the degree of LH depletion and the higher amount of FSH 
ampoules needed for the stimulation.103
LH and FSH stimulation in HH women
Since there is no doubt about a FSH threshold level, an 
equally minimum LH level necessary for normal follicular 
growth in IVF and HH patients was debated. Although the 
discussion has been limited to the comparison between 
downregulated IVF patient and HH women, the attempts 
to improve pregnancy rates still focus on the effect of 
endogenous and exogenous LH.
The first studies in ovulation induction dealing with this 
topic utilized HMG15,53,68,71 or HCG107 as the only source of 
LH then available. These first studies showed the dependency 
of the maturing follicle on LH and FSH. As mentioned above, 
HMG has a fixed LH/FSH ratio without the chance to adjust 
the amount of LH and FSH for the stimulation protocol. 
With the introduction of recombinant FSH and LH, the 
possibility of an individually adjusted dosage and tailored 
LH/FSH ratio became available. Several studies have been 
conducted to prove the benefit of an LH and FSH combined 
stimulation in HH women 48,103,104,106,108 and the value of the 
LH threshold level.102
These studies provide results of high clinical relevance 
and will be discussed to briefly.
1.  The European Recombinant Human LH Study Group 
first published their data in 1998.104 Thirty-eight women 
with HH were enrolled in the study and randomized into 
4 LH treatment groups (Table 1.)
  All groups received a fixed FSH stimulation dose of 
150 units (U) daily. In the placebo and the 25 U LH Biologics: Targets & Therapy 2009:3 343
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group, stimulation failed to induce sufficient follicular 
growth, with poor ovulation rates, and no pregnancy 
could be achieved. In the 75 and 225 U LH group, 80% to 
100% received HCG to trigger ovulation, and 3 pregnan-
cies were reported. Comparing the 75 and 225 U groups, 
stimulation with 225 U LH showed higher estradiol levels 
with a lower follicle count. This “ceiling” effect of LH 
will be discussed later. This was the first study that inves-
tigated intensively the influence of LH supplementation 
on FSH stimulation in HH women.
2.  Shoham et al106 reported on a study, including 39 patients, 
to compare FSH-only stimulation with a combined 
FSH/LH stimulation, both with a fixed FSH dosage 
of 150 U daily. The LH group showed a much higher 
success in follicular growth than the FSH-only group 
(Table 2.)
Both studies demonstrated an impressive enhancement 
of follicular growth through LH supplementation.
Burgues et al,103 Kaufmann et al1 and O’Dea et al108 
investigated the ability of LH/FSH combined stimulation to 
adjust gonadotropin dosage. All studies reported on compa-
rable results of follicular growth (74%–87%), with a clinical 
pregnancy rate of 22% per HCG given cycle and a cumulative 
pregnancy rate (up to 3 cycles) of 74%.
The overall results from these studies demonstrate a clear 
benefit of LH in the stimulation of HH women. Besides 
a reduction in FSH ampoules needed,103 all investigators 
reported on high rates of normal follicular growth, from 
66% to 87%.1,103,106,108 Through the action of LH and 
even in the presence of high FSH stimulation, a trend 
toward fewer midsized follicles or a less severe ovarian 
over-response could be observed,1,48 and subsequently a 
lower risk of an ovarian hyperstimulation syndrome and/or 
multiple pregnancies.67 Ovulation rates reached were also 
very high (up to 90%).103,104 Compared with a FSH-only 
stimulation, the addition of LH led to higher preovulatory 
estradiol levels48,104 and a better endometrium score.106 The 
mid-luteal progesterone levels were found to be two-fold 
higher in the FSH/LH group than in the FSH-only group.1 
Pregnancy rates per cycle reached 22%103 and 29%,104 and 
a cumulative pregnancy rate of 74% over a maximum of 
3 treatment cycles was achieved.108
These study results gave interesting insights into the 
mechanisms of proper follicular growth and the minimum 
(and maximum) amounts of LH and FSH needed to ensure 
a normal follicular growth.
The studies with HH women showed a clear dependency 
of normal follicular growth on a distinct amount of LH, 
the LH threshold level.102 The value of this threshold level 
was calculated with 1.2 U/L106 and rejected.104 Due to the 
limitations of the measurement of a hormone and particu-
larly near the lower detection level, these different points 
of view reflect partly the difficulties of comparing hormone 
levels from different laboratories with different methods. 
Therefore, the measurement of circulating immunoreac-
tive LH has only limited value to detect a LH-insufficient 
patient.81,103,105 From a more practical viewpoint, Burgues 
et al103 recommended a stimulation with 75 U LH daily in 
HH women with basal LH levels above 1 U/L and a higher 
LH dosage in women with more profound LH depletion. 
On the other hand, another group reported on a sufficient 
stimulation with 75 U of LH daily in HH women with LH 
levels below 1 U/L, and these LH levels did not rise during 
stimulation.104 Both groups utilized 150 U FSH for daily 
injection. The debate on the LH threshold level will go 
further with the publication of new studies. Until now, the 
great value of substituting stimulation with LH for FSH in 
HH women has been clearly described and should become 
established in normal practice.
All those studies showed convincingly that FSH stimu-
lation supplemented with recombinant LH is superior to 
FSH-only stimulation in HH women.
With the availability of recombinant LH, another LH-
related concept could be proved: the LH “ceiling” effect.86 
And, in fact, an increasing LH dosage will be able to 
minimize or stop the additional development of midsized 
follicles and reduce or avoid multiple ovulations.48,104 With 
the occurrence of LH receptors on granulosa cells, LH-only 
Table 1 Treatment and stimulation outcome104
No. patients  LH dosage 
(Units)
Ovulation  
induction (%)
Estradiol 
(pmol/L)
8 0 0* 60
7 25 33* 89
9 75 80* 855
10 225 100* 1598
*p = 0.01.
Table 2 Treatment and stimulation outcome106
No. patients  LH dosage 
(Units)
Follicular 
growth (%)
Estradiol 
(pmol/L)
13 0 2 (15,4%)* 370
26 75 17 (65.4%)* 1240
*p = 0.006.Biologics: Targets & Therapy 2009:3 344
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stimulation will be able to sustain follicular growth, but only 
at high levels.47,48
The LH “ceiling” concept could be an interesting 
alternative in case of unwanted multiple follicular growths. 
The cessation of FSH stimulation and a high LH dosage 
enables a reduction in follicle count, and could avoid or even 
limit multiple ovulations and therefore minimize the risk 
of an ovarian hyperstimulation syndrome and/or multiple 
pregnancies.67
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